Anika Therapeutics, Inc. (ANIK)
19.10
-0.26
(-1.34%)
USD |
NASDAQ |
Oct 02, 16:00
19.12
+0.02
(+0.10%)
After-Hours: 20:00
Anika Therapeutics Net Income (Quarterly) : 3.309M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.309M |
| March 31, 2026 | -5.056M |
| December 31, 2025 | 1.801M |
| September 30, 2025 | -3.175M |
| June 30, 2025 | -4.647M |
| March 31, 2025 | -3.958M |
| December 31, 2024 | -2.486M |
| September 30, 2024 | -1.845M |
| June 30, 2024 | -2.541M |
| March 31, 2024 | -1.956M |
| December 31, 2023 | -2.37M |
| September 30, 2023 | -6.576M |
| June 30, 2023 | -2.741M |
| March 31, 2023 | -10.35M |
| December 31, 2022 | -4.908M |
| September 30, 2022 | -4.175M |
| June 30, 2022 | -2.843M |
| March 31, 2022 | -2.933M |
| December 31, 2021 | -5.793M |
| September 30, 2021 | 0.558M |
| June 30, 2021 | 6.531M |
| March 31, 2021 | 2.838M |
| December 31, 2020 | -15.66M |
| September 30, 2020 | -6.411M |
| June 30, 2020 | -7.708M |
| Date | Value |
|---|---|
| March 31, 2020 | 5.793M |
| December 31, 2019 | 4.051M |
| September 30, 2019 | 9.20M |
| June 30, 2019 | 9.435M |
| March 31, 2019 | 4.507M |
| December 31, 2018 | 7.717M |
| September 30, 2018 | 7.599M |
| June 30, 2018 | 10.09M |
| March 31, 2018 | -6.686M |
| December 31, 2017 | 8.067M |
| September 30, 2017 | 6.887M |
| June 30, 2017 | 11.37M |
| March 31, 2017 | 5.493M |
| December 31, 2016 | 8.085M |
| September 30, 2016 | 8.952M |
| June 30, 2016 | 8.615M |
| March 31, 2016 | 6.895M |
| December 31, 2015 | 11.04M |
| September 30, 2015 | 8.380M |
| June 30, 2015 | 7.820M |
| March 31, 2015 | 3.516M |
| December 31, 2014 | 7.816M |
| September 30, 2014 | 6.171M |
| June 30, 2014 | 9.302M |
| March 31, 2014 | 15.03M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Precigen, Inc. | 20.07M |
| Repligen Corp. | 5.008M |
| Amgen, Inc. | 2.375B |
| Biogen, Inc. | 97.50M |
| BioMarin Pharmaceutical, Inc. | 44.76M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 32.61M |
| Total Expenses (Quarterly) | 29.30M |
| EPS Diluted (Quarterly) | 0.2412 |
| Enterprise Value | 242.45M |
| Gross Profit Margin (Quarterly) | 65.15% |
| Profit Margin (Quarterly) | 10.15% |
| Earnings Yield | -1.44% |
| Normalized Earnings Yield | -1.435 |